WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response
Paige, Adam J.W.
MetadataShow full item record
AbstractThere are clear gaps in our understanding of genes and pathways through which cancer cells facilitate survival strategies as they become chemoresistant. Paclitaxel is used in the treatment of many cancers, but development of drug resistance is common. Along with being an antimitotic agent paclitaxel also activates endoplasmic reticulum (ER) stress. Here, we examine the role of WWOX (WW domain containing oxidoreductase), a gene frequently lost in several cancers, in mediating paclitaxel response. We examine the ER stress-mediated apoptotic response to paclitaxel in WWOX-transfected epithelial ovarian cancer (EOC) cells and following siRNA knockdown of WWOX. We show that WWOX-induced apoptosis following exposure of EOC cells to paclitaxel is related to ER stress and independent of the antimitotic action of taxanes. The apoptotic response to ER stress induced by WWOX re-expression could be reversed by WWOX siRNA in EOC cells. We report that paclitaxel treatment activates both the IRE-1 and PERK kinases and that the increase in paclitaxel-mediated cell death through WWOX is dependent on active ER stress pathway. Log-rank analysis of overall survival (OS) and progression-free survival (PFS) in two prominent EOC microarray data sets (Tothill and The Cancer Genome Atlas), encompassing ~800 patients in total, confirmed clinical relevance to our findings. High WWOX mRNA expression predicted longer OS and PFS in patients treated with paclitaxel, but not in patients who were treated with only cisplatin. The association of WWOX and survival was dependent on the expression level of glucose-related protein 78 (GRP78), a key ER stress marker in paclitaxel-treated patients. We conclude that WWOX sensitises EOC to paclitaxel via ER stress-induced apoptosis, and predicts clinical outcome in patients. Thus, ER stress response mechanisms could be targeted to overcome chemoresistance in cancer.
CitationJanczar S, Nautiyal J, Xiao Y, Curry E, Sun M, Zanini E, Paige AJ, Gabra H (2017) 'WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response', Cell Death and Disease, 8 (7), pp.e2955.
JournalCell Death and Disease
PubMed Central IDPMC5550887
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Green - can archive pre-print and post-print or publisher's version/PDF
- Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
- Authors: Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A
- Issue date: 2012 Apr
- Aberrant expression of WWOX protein in epithelial ovarian cancer: a clinicopathologic and immunohistochemical study.
- Authors: Lan C, Chenggang W, Yulan B, Xiaohui D, Junhui Z, Xiao W
- Issue date: 2012 Mar
- [Effects of WWOX gene transfection on cell growth of epithelial ovarian cancer].
- Authors: Yan HC, Xue JQ, Lu XY, Wan MR, Feng X, Liu XY
- Issue date: 2008 May
- Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
- Authors: Gaikwad SM, Thakur B, Sakpal A, Singh RK, Ray P
- Issue date: 2015 Apr
- Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.
- Authors: Chiang YC, Lin HW, Chang CF, Chang MC, Fu CF, Chen TC, Hsieh SF, Chen CA, Cheng WF
- Issue date: 2015 Nov 24